Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) EBITDA (2016 - 2017)

Historic EBITDA for Bone Biologics (BBLG) over the last 2 years, with Q4 2017 value amounting to -$1.3 million.

  • Bone Biologics' EBITDA rose 5791.57% to -$1.3 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$2.6 million, marking a year-over-year increase of 8713.24%. This contributed to the annual value of -$1.1 million for FY2021, which is 3370.39% down from last year.
  • According to the latest figures from Q4 2017, Bone Biologics' EBITDA is -$1.3 million, which was up 5791.57% from -$1.1 million recorded in Q3 2017.
  • Bone Biologics' EBITDA's 5-year high stood at $2.0 million during Q2 2017, with a 5-year trough of -$9.1 million in Q1 2016.